SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

ZANETTI, Flavia et al. Obtención y evaluación preliminar de un virus canarypox recombinante como candidato a vacuna antirrábica. Rev. argent. microbiol. [online]. 2012, vol.44, n.2, pp. 75-84. ISSN 0325-7541.

    2. Bout-Cararo C, Contreras V, Fournier A, Jallet C, Guibert J, Dubois E, Thiery R, Breard E, Tordo N, Richardson J, Schwartz-Cornil I, Zientara S, Klonjkowski B. Canine adenoviruses elicit both humoral and cell-mediated immune responses against rabies following immunization of sheep. Vaccine 2011; 29: 1304-10. [ Links ]

    3. Cadoz M, Meignier B, Plotkin S, Strady A, Taylor J, Tartaglia J, Paoletti E, Plotkin S. Immunization with canarypox virus expressing rabies glycoprotein. Lancet 1992; 339:1429-32. [ Links ]

    4. Cenna J, Tan G, Papaneri A, Dietzschold B, Schnelly M, McGettigan J. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine 2008; 26:6405-14. [ Links ]

    6. Cox J, Dietzschold B, Schneider L. Rabies virus glycoprotein II. Biological and serological characterization. Infect Immun 1977;16:754-9. [ Links ]

    7. Deilaporta S, Word J, Hicks J. A plant molecular DNA minipreparation, versin II. Plant Mol Biol Rep 1983; 1:12-21. [ Links ]

    8. Esposito J, Brechling K, Baer G, Moss B. Vaccinia virus recombinants expressing rabies glycoprotein protect against rabies. Virus Gene 1987; 1: 7-21. [ Links ]

    9. Esposito J, Knight J, Shaddock J, Novembre F, Baer G. Successful oral rabies vaccination of racoons with raccons poxvirus recombinants expressing rabies virus glycoproteins. Virology 1988; 165: 313-6. [ Links ]

    10. Faber M, Pulmanausahakul R, Hodawadekar S, Spitsin S, McGetiggan J, Schnell M, Dietzchold B. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J Virol 2002; 76: 3374-81. [ Links ]

    11. Ferrer F, Zanetti F, Calamante G. Diseo y construccin de vectores de transferencia para la obtencin de virus vaccinia Ankara modificado (MVA) recombinantes. Rev Argent Microbiol 2007; 39:138-42. [ Links ]

    13. Fries L, Tartaglia J, Taylor J, Kauffman E, Meignier B, Paoletti E, Plotkin S. Human safety and immunogenicity of canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996; 14: 428-34. [ Links ]

    14. Fu Z, Dietzschold B, Schumacher C, Wunner W, Ertl, H, Koprowski H. Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine. Proc Natl Acad Sei USA1991; 88: 2001-5. [ Links ]

    15. Henderson H, Jackson F, Bean K, Panasuk B, Niezgoda M, Slate D, Li J, Dietzschold B, Mattis J, Rupprecht C. Oral immunization of raccons and skunks with a canine adenovirus recombinant rabies vaccine. Vaccine 2009; 27: 7194-7. [ Links ]

    16. Hu R, Zhang S, Fooks A, Yuan H, Liu Y, Li H, Tu C, Xia X, Xiao Y. Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. Microb Infect 2006; 8:1090-7. [ Links ]

    17. Kawano H, Mifune K, Ohuchi M, Mannen K, Cho S, Hiramatsu K, Schichijo A. Protection against rabies in mice by cytotoxic T cell clone recognizing the glycoprotein of rabies virus. J Gen Virol 1990; 71: 281 -7. [ Links ]

    18. Kieny M, Lathe R, Drillien R, Spehner D, Skory S, Schmitt D, Wiktor T, Koprowski H, Lecocq J. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984;312:163-6. [ Links ]

    19. Li J, Faber M, Papaneri A, Faber M-L, McGettigan J, Schnell M, Dietzschold B. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology 2006; 356:147-54. [ Links ]

    20. Macfarlan R, Dietzschold B, Koprowski H. Stimulation of cytotoxic T-lymphocyte responses by rabies virus glycoprotein and identification of an immunodominant domain. J Mol Immunol 1986;23:733-41. [ Links ]

    23. Poulet H, Minke J, Pardo M, JuillardV, Nordgren B, Audonnet J-C. Development and registration of recombinant veterinary vaccine, the example of the canarypox vector plataform. Vaccine 2007; 25: 5606-12. [ Links ]

    24. Preveo L, Campbell J, Christie B, Bibek L, Graham F. A recombinant human adenovirus vaccine against rabies. J Infect Dis 1990; 161:27-30. [ Links ]

    25. Reed L, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493-7. [ Links ]

    26. Somogyi P, Frasier J, Skinner M. Fowlpox virus host range restriction: gene expression, DNA replication and morphogenesis in nonpermissive mammalian cells. Virology 1993; 197: 439-44. [ Links ]

    27. Takida-SonodaY, Fujii H, Mifune K, ItoY, Hiraga M, Nishizono A, Mannen K, Minamoto N. Resistance of mice vaccinated with rabies virus internal structural proteins to lethal infection. Arch Virol 1993; 132:51-65. [ Links ]

    28. Taylor J, Meignier B, Tartaglia J, Languet B, VanderHoeven J, Franchini G, Trimarchi C, Paoletti E. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 1995; 13:539-49. [ Links ]

    29. Taylor J, Trimarchi C, Weinberg R, Languet B, Guillemin F, Desmettre P, Paoletti E. Efficacy study on a canarypox-rabies recombinant virus. Vaccine 1991; 9:190-3. [ Links ]

    30. Taylor J, Weinberg R, Languet B, Desmettre P, Paoletti E. A recombinant fowlpox virus inducing protective immunity in non-avain species. Vaccine 1988; 6: 497-503. [ Links ]

    31. Tollis M, Dietzschold B, Viola C, Koprowski H. Immunization of monkeys with rabies ribonucleoprotein (RNP) confers protective immunity against rabies. Vaccine 1991; 9:134-6. [ Links ]

    32. Tordo N, Bahloul C, Jacob Y, Ballet C, Perrin P, Badrane H. Rabies: epidemiological tendencies and control tools. Dev Biol (Basel) 2006; 125: 3-13. [ Links ]

    33. Tulman E, Afonso C, Lu Z, Zsak L, Kutish G, Rock D.The genome of canarypox virus. J Virol 2004; 78: 353-66. [ Links ]

    34. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccine 2010; 9: 997-1005. [ Links ]

    37. Wiktor T, Macfarlan R, Reagan K, Dietzschold B, Curtis P, Wunner W, Kieny M, Lathe R, Lecocq J, Mackett M, Moss B, Koprowski H. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci USA 1984; 81: 7194-8. [ Links ]

    39. Wiktor T. Cell-mediated immunity and post-exposure protection from rabies by inactivated vaccine of tissue culture origin. Dev Biol Stand 1977; 40:225-30. [ Links ]

    43. Xuan X, Tuchiya K, Sato I, Nishikawa Y, Onoderaz Y, Takashima Y, Yamamoto A. Biological and immunogenic properties of rabies virus glycoprotein expressed by canine herpesvirus vector. Vaccine 1998; 16: 969-76. [ Links ]

    44. Yuan Z, Zhang S, Liu Y, Zhang F, Fooks A, Li Q, Hu R. A recombinant Pseudorabies virus expressing rabies virus glycoprotein: Safety and immunogenicity. Vaccine 2008; 26: 1314-21. [ Links ]